of patients, which in turn have resulted in long-term disease control and also giving hope of a cure in the future. 8 Clinical outcomes improved with the introduction of high-dose melphalan with autologous stem cell support (HDM-ASCT) which was developed in the 1980s and 1990s 9, 10 and was followed by a range of modern drugs which started around the turn of the twenty-first century. Today, multiple myeloma can be treated with several classes of drugs such as proteasome inhibitors (bortezomib, carfilzomib, and ixazomib), immunomodulatory drugs (thalidomide, lenalidomide, and pomalidomide), cytotoxic drugs (cyclophosphamide and melphalan, as well as other combinations such as DCEP and VTD-PACE), HDAC inhibitors (panobinostat), naked monoclonal antibodies (daratumumab, elotuzumab), and allogeneic transplant. In addition to these classes of drugs, several newer drugs are already far along in clinical development including the development of antibody conjugates, bite antibodies, targeted small molecules, and CAR-T cell therapy.
As part of the approval process for the newer drugs, randomized phase 3 trials have consistently shown improvement and, in particular, when these clinical trials were conducted in countries with limited access to newer drugs (ie with limited options to retreat progressing disease) increased overall survival with many of these newer drugs. [11] [12] [13] [14] [15] However, due to the nature of eligibility criteria of clinical trials, it is difficult to generalize the results from the studies to all multiple myeloma patients diagnosed in the general population. For example, elderly patients and patients with comorbidities are often excluded from clinical trials, and population-based studies are needed to fully evaluate the impact of the new treatment modalities on survival in unselected patients. The aims of this study are to review patterns of incidence and survival in multiple myeloma in the general population.
| ME THODS
We searched PubMed for studies using the search words multiple myeloma and trends in incidence and multiple myeloma and trends in survival with publication date between January 1, 2000 and June 30, 2017 and identified 240 and 305 papers, respectively. We examined abstracts and text to identify papers that were based on regional or national registries, compared changes over a time period of more than 5 years, and covered a period reaching year 2000 or later. Eleven studies on trends in incidence and 17 studies on trends in survival fulfilled these criteria.
In a subanalysis, for comparison, 6 large, non-population-based, single-institution studies of survival trends were included.
| RE SULTS

| Incidence trends
Incidence and mortality rates obtained from population registries show a great variation around the world. Several studies have reported a dramatic increase in multiple myeloma incidence and mortality in the second half of the twentieth century. In the USA, there was a 2-fold to 3-fold increase in multiple myeloma mortality from 1950 to 1975. The increase was seen in both races, but was greater in non-whites than whites and primarily occurred in people over 55 years of age. 16 In England and Wales, the age-adjusted mortality increased more than 5-fold from 1950 to 1979. 17 In contrast, two studies from Minnesota, USA, and Malmö, Sweden, found no increase in age-adjusted multiple myeloma incidence from 1945 to 2001 and from 1950 to 2005, respectively. 2, 3 These studies were based on data from defined populations with a high access to health care and well-developed registration systems. They also reported increasing age-specific incidence rates with advancing age including in the very old.
In a more recent study using SEER (NCI Surveillance Epidemiology and End Results 9 Registries Database) data covering the period 1973 to 2005, multiple myeloma incidence rates in the USA rose slightly from the 1970s to the 1990s before flattening in recent years. 18 In a later study from the SEER, age-adjusted incidence increased slightly from 5.5 to 6.1 per 100 000 person-years between the calendar periods 1993-1997 and 1998-2002. 19 In Sweden, the age-adjusted multiple myeloma incidence increased during the first decade of reporting (1960) (1961) (1962) (1963) (1964) (1965) (1966) (1967) (1968) (1969) (1970) and remained stable thereafter. 6, 20 In Great Britain, the age-adjusted annual incidence (European stan- 21 The largest increase in Great Britain was in the age group 70-79 years.
In Asia, where the incidence of multiple myeloma is lower, the increase over time has been more pronounced. In Korea, the ageadjusted incidence (world standard) in the period 1999-2010 was 
| Survival trends
Improvements in multiple myeloma survival in the general population following introduction of newer drugs were first reported over 10 years ago in a large study from Sweden. 25 In that study, survival patterns were evaluated for 14 381 multiple myeloma patients di- to increase from 73% to 83% and from 31% to 36%, respectively.
When evaluating survival patterns by age, the 1-year RSR improved in all age groups, but improvement in 5-and 10-year RSR was restricted to patients 60 years or younger. The study used data from the Swedish Cancer Registry with high completeness (95%) and accuracy (98%) for multiple myeloma in a validation study. 26 In that first study from 2007, there was no detailed information on treatment available ( Two studies that reported observed survival and one study reporting myeloma-specific survival included.
the authors found an increase in 5-year relative survival from 28.8% to 34.7%. However, the improvement was seen mainly in patients younger than 60 years at diagnosis and was modest and not significant in those over 60. There was no information on treatment, but the authors speculated that the improvement was mainly an effect of the introduction of HDM-ASCT. 28 In another study, a racial disparity in trends of survival was noted in patients from the SEER da- 29 In an analysis of SEER data, covering 4 calendar periods from 1973 to 2009 and 4 age cohorts, 5-year myelomaspecific survival increased in all age groups. The improvement was most evident in the younger age groups reaching 58% in the age cohort 51-65 years and decreased with advancing age with no improvement in patients aged 80 years or more. 30 As myeloma-specific survival, which depends on the accuracy of death certificates, was used, it is difficult to compare with other studies.
In a study using data from 11 population-based cancer registries Five-year relative survival increased from 36% to 47% in men and from 40% to 56% in women. The increase was seen in all age groups and was significant also in those 60 years or older. 36 An improvement in relative survival was reported from two regional cancer registries in Northern Netherlands. Five-year relative survival increased in patients younger than 65 years from 34% in those diagnosed 1989-1992 to 56% in those diagnosed 2001-2005.
There was no improvement in the older. The authors concluded that the improvement in the younger likely is related to the introduction of HDM-ASCT. 37 Interestingly, in this study, there was a distinct agerelated difference in the proportion of patients included in clinical trials. Thirty-eight percent of patients younger than 65 years were included in clinical trials vs 5% of those 65 years or older.
In a report from the Granada Cancer Registry in Spain, the median overall survival increased from 17.7 months in patients diag- .8% which is considerably lower than that reported from the USA and Europe; however, survival rates were reported to be combined for all age groups, and there was no age-stratified information on relative survival for younger and older patients. In Japan, thalidomide, bortezomib, and lenalidomide were not approved during the period under study. However, patients receiving conventional treatment were older, and comorbidity was not registered. There was no improvement of overall survival over time. 
| Preliminary data on prevalence
As a consequence of both increasing number of multiple myeloma patients due to aging populations and improved survival, the prevalence of multiple myeloma has increased substantially in many countries. In Sweden, the prevalence increased from 13.1 per 100 000 (in 1980) to 34.8 per 100 000 (in 2014). 6 During the same calendar period, the 5-year relative survival increased from 29% to 49%.
Similarly, in Denmark, the prevalence increased more than 3-fold from 1980 to 2012. 46 A large proportion of these patients are elderly with significant age-related comorbidity which, clinically, has direct implications on therapeutic decision making, choice of therapy, and goals of treatment.
| D ISCUSS I ON
The multiple myeloma landscape has changed dramatically in the past 50 years. Several studies have reported an increasing ageadjusted incidence during the second half of the twentieth century with a tendency to level off in the last decades. Other studies based on data from defined populations with a high access to health care and a careful registration system, however, indicate that the ageadjusted incidence has remained stable and reported increases can be explained by better case ascertainment, especially among the elderly. Yet the crude incidence and prevalence have increased dramatically in the USA and Europe due to both the aging population and the steep increase in age-specific incidence with advancing age which is even more pronounced in multiple myeloma than of the addition of bortezomib to the combination of melphalan and prednisone, which is commonly used in Europe and Asia. In the VISTA trial, the median age was only 71 years although very few patients below 65 years were included. 15 Similar exclusion criteria were applied in most other clinical trials. In fact, similar limitations exist also to some extent in reports from large referral centers.
For example, the Mayo Clinic has reported a successive improvement of overall survival, initially restricted to younger patients but recently also in the older. 42 The median age of the Mayo Clinic improved progression-free survival in patients with relapsed or relapsed and refractory myeloma. 11, 47 Progression-free survival was also significantly prolonged in relapsed/refractory myeloma patients by the combination of lenalidomide and dexamethasone with either the second-generation i v proteasome inhibitor carfilzomib 48 or the oral proteasome inhibitor ixazomib. 49 Trials are underway of these and other regimes in up-front treatment of multiple myeloma.
The growing evidence that achievement of a high-quality response assessed by minimal residual disease (MRD) is associated with improved survival will lead to new strategies with more intensive treatment up-front and hopefully further improve survival. 8 Access to drugs varies around the world due to differences in approval and reimbursement systems. Important global challenges include the dilemma with two key aspects: (i) an unmet need for rapid drug development and patient access to new drugs, on the one hand, and (ii) a need for sustainable costs-for both the individual and society, on the other hand. These are highly complex aspects and there is not "one right solution" for every country or region. In our opinion, population-based data will most likely become increasingly important as it can help to guide local decision making and policies.
| Summary/conclusion
The age-adjusted incidence rate of multiple myeloma is stable in populations with good case ascertainment, but the crude inci- 
